| 摘要 |
1. Amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1-2 of the naturally-occurring RANTES having amino acid SEQ ID No:2 and having chemokine antagonistic activity MCP-3, MCP-1alpha, MCP-1beta and RANTES. 2. Amino-terminally truncated MCP-2 according to one or more of the preceding claims, in a glycosylated form. 3. DNA molecules coding for the amino-terminally truncated RANTES according to claims 1 or 2. 4. An expression vector which comprises the DNA molecule according to claim 3. 5. A host cell comprising the expression vector according to claim 4. 6. A recombinant process for preparing a protein according to claim 1 or 2, comprising cells culturing according to claim 5 in an appropriate culture medium and isolating the expression product. 7. Use of a protein according to claims 1 or 2 as a medicament the therapy of which is based on the chemokine antagonistic activity MCP-3, MCP-1alpha, MCP-1beta and RANTES. 8. Use of a protein according to claims 1 or 2 in the manufacture of a medicament the therapy and/or diagnosis of diseases, the therapy of which is based on the chemokine antagonistic activity MCP-3, MCP-1alpha, MCP-1beta and RANTES. 9. Use of a protein according to claim 8 in the manufacture of a medicament for the treatment of inflammatory diseases, HIV-infection, angiogenisis- and hematopoiesis-related diseases, and tumors. 10. A pharmaceutical composition comprising the protein according to any of the claims 1 or 2 together with one or more pharmaceutically acceptable carriers and/or excipients, the therapy of which is based on the chemokine antagonistic activity MCP-3, MCP-1alpha, MCP-1beta and RANTES. |
